1] Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Ave., Cambridge, Massachusetts 02139, USA. [2] David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Ave., Cambridge, Massachusetts 02139, USA. [3] Department of Anesthesiology, Boston Children's Hospital, 300 Longwood Ave., Boston, Massachusetts 02115, USA. [4].
1] David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Ave., Cambridge, Massachusetts 02139, USA. [2] Department of Anesthesiology, Boston Children's Hospital, 300 Longwood Ave., Boston, Massachusetts 02115, USA. [3].
Nat Rev Drug Discov. 2015 Jan;14(1):45-57. doi: 10.1038/nrd4477. Epub 2014 Nov 28.
Nanotechnology-based approaches hold substantial potential for improving the care of patients with diabetes. Nanoparticles are being developed as imaging contrast agents to assist in the early diagnosis of type 1 diabetes. Glucose nanosensors are being incorporated in implantable devices that enable more accurate and patient-friendly real-time tracking of blood glucose levels, and are also providing the basis for glucose-responsive nanoparticles that better mimic the body's physiological needs for insulin. Finally, nanotechnology is being used in non-invasive approaches to insulin delivery and to engineer more effective vaccine, cell and gene therapies for type 1 diabetes. Here, we analyse the current state of these approaches and discuss key issues for their translation to clinical practice.
基于纳米技术的方法在改善糖尿病患者的治疗方面具有巨大潜力。正在开发纳米颗粒作为成像对比剂,以帮助早期诊断 1 型糖尿病。葡萄糖纳米传感器被整合到可植入设备中,以更准确和更方便患者的方式实时跟踪血糖水平,同时也为葡萄糖响应性纳米颗粒提供了基础,这些纳米颗粒更好地模拟了身体对胰岛素的生理需求。最后,纳米技术被用于非侵入性的胰岛素输送方法,并用于设计更有效的疫苗、细胞和基因疗法,以治疗 1 型糖尿病。在这里,我们分析了这些方法的现状,并讨论了将其转化为临床实践的关键问题。